The STING pathway targeting technologies market, featuring a healthy pipeline of therapeutics, predicts Roots Analysis Report Keywords- STING Pathway, Targeting Therapeutics, Therapeutics, Roots Analysis, Research STING, having generated significant interest within the medical research community, is currently considered one of the fastest growing areas of cancer immunotherapy and is being pursued by several large pharmaceutical companies Roots Analysis is pleased to announce the publication of its recent study, titled, “STING Pathway Targeting Therapeutics and Technologies, 2020-2030.” The report features an extensive study of the current market landscape and future potential of these therapeutics and affiliated technologies, over the next decade. This study focuses specifically on small molecule STING modulators. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of therapeutics targeting STING Pathway.  A detailed assessment of the current market landscape of various technology platforms that are being actively used for the development of STING modulators.  Detailed profiles of developers of therapeutics targeting STING pathway (shortlisted on the basis of phase of development of pipeline products).  An in-depth analysis of more than 280 grants that have been awarded to research institutes engaged in STING pathway targeting therapeutics-related projects.  An analysis of the initiatives of big pharma players engaged in this domain.  An analysis of the start-ups / small players (established in the last ten years, less than 50 employees) engaged in the development of STING pathway targeting therapeutics.  A detailed publication analysis of more than 300 peer-reviewed, scientific articles that have been published during the period 2019 - Q1 2020.  An analysis of the partnerships that have been established in this domain, in the recent past.  An analysis of the investments made in this domain.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below)  Types of Payment  Upfront Payments  Milestone Payments  Type of STING Modulator  Agonist  Antagonist  Key Therapeutic Area(s)  Oncological Disorders  Inflammatory Disorders  Infectious Diseases  Others  Route of Administration  Intratumoral  Intravenous  Oral  Subcutaneous  Others  Type of Molecule  Non-nucleotide  Cyclic Dinucleotide  Live Biotherapeutics  Oncolytic Peptides  Synthetic Peptides  Others  Key Geographical Regions  North America  Europe  Asia-Pacific Key companies covered in the report  Aduro Biotech  Bristol Myers Squibb  Eisai  GlaxoSmithKline  ImmuneSensor Therapeutics  Merck  Noxopharm  Spring Bank Pharmaceuticals  Synlogic For more information please click on the following link: https://www.rootsanalysis.com/reports/sting-pathway-targeting-therapeutics-and-technologies-market.html Other Recent Offerings 1. Nuclear Medicine and Radiopharmaceuticals Manufacturing Market, 2020-2030 2. Global Psychedelic Therapeutics Market by Type of Psychedelic Substance (Ketamine, Psilocybin, MDMA and Others), by Origin (Natural and Synthetic), by Type of Therapy (Monotherapy, Combination and Others), by Route of Administration (Oral, Intravenous, Intranasal and Others) and by Key Geographies (North America, Europe and Asia- Pacific and rest of the world): Industry Trends and Global Forecasts, 2020-2030 3. Endocannabinoid System Targeted Therapeutics Market, 2020-2030 Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis

The antibody contract manufacturing market at an annualized rate of 12%. {claims Roots Analysis} Report Keywords - Antibody Contract, Contract, Manufacturing Market, RootsAnalysis, Report With over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for developing and manufacturing of such products is anticipated to increase beyond the capabilities of innovator companies alone Roots Analysis has announced the addition of the “Antibody Contract Manufacturing Market, 2020-2030” report to its list of offerings. Although biopharmaceuticals offer significant profit margins and have been proven to be effective in treating a myriad of diseases, they are generally associated with high costs of development and complex manufacturing protocols; this is true for antibody-based products as well. Presently, there are a number of companies that claim to offer end-to-end solutions, ranging from antibody development to commercial production. Further, prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing. Key Market Insights Over 100 CMOs presently claim to offer manufacturing services for antibodies The antibody contract manufacturing market is currently dominated by the presence of small and mid-sized companies, which represent 70% of the industry stakeholders. It is also worth highlighting that more than 55% of CMOs claim to have the capabilities to manufacture antibodies across all scales of operation (preclinical, clinical and commercial). More than 90% service providers are focused on the production of monoclonal antibodies However, players based in Asia are now increasingly focusing on the development of bispecific antibodies for therapeutic use. It worth highlighting that close to 20% of the CMOs engaged in this domain claim to offer manufacturing services for both bispecific antibodies and antibody fragments. For more Insightful Information - https://www.rootsanalysis.com/reports/view_document/antibody-cmo-market/295.html Europe has emerged as a key manufacturing hub for antibody-based products More than 120 manufacturing facilities have been established by various players, worldwide; of these, 40% are in Europe. Additionally, 40% of the total installed capacity is in Europe, followed by Asia. Some of the prominent regions in Asia include (in decreasing order of number of manufacturing facilities) China, South Korea, India, Japan and Taiwan. More than 90 partnership agreements have been inked between 2013 and 2019 Majority of these agreements were focused on manufacturing of various types of antibodies. Other popular types of collaboration models include process development and manufacturing agreements (22%), product development and manufacturing agreements (10%) and licensing agreements (7%). Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 ben.johnson@rootsanalysis.com LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis

The global autoinjectors market is projected to grow at an annualized rate of over 10%, till 2030 Report Keywords - global autoinjectors, Global Autoinjectors Market, Roots Analysis, Market Report Autoinjectors have become an important part of modern healthcare, having demonstrated the potential to address a number of parenteral drug delivery related adverse events, and improve medication adherence among patients Roots Analysis is pleased to announce the publication of its recent study, titled, “Global Autoinjectors Market (3rd Edition), 2020-2030.” The report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of autoinjectors over the next decade. The report features an in-depth analysis, highlighting the diverse capabilities of stakeholders engaged in this domain. In addition to other elements, the study includes:  A detailed assessment of the current market landscape of developers engaged in the development and / or manufacturing autoinjectors.  A detailed assessment of current landscape of companies that are developing drugs in combination with autoinjectors.  A competitiveness analysis of various disposable and reusable autoinjectors.  A detailed brand positioning analysis of leading industry players highlighting the current perceptions regarding their proprietary brands.  A list of marketed drugs / therapies and pipeline candidates that are likely to be developed in combination with autoinjectors in the near future.  A list of key opinion leaders (KOLs) within this domain with significant contributions in clinical trials and filing patent applications.  Detailed case studies on the most commonly targeted indications of the approved autoinjector products.  A case study on the role of CMOs offering services for drug delivery devices.  A SWOT analysis capturing the key parameters and trends that are likely to influence the future of autoinjectors market.  Elaborate profiles of autoinjector manufacturers that have more than three devices in their respective product portfolios.  A detailed market forecast, featuring analysis of the current and projected future opportunity across key market segments (listed below) To request a customize report - https://www.rootsanalysis.com/reports/autoinjectors-market/request-customization.html  Usability  Disposable  Reusable  Route of Administration  Subcutaneous  Intramuscular  Type of Molecule  Monoclonal Antibody  Peptide  Protein  Small Molecule  Therapeutic Indication  Anaphylaxis  Asthma  Multiple Sclerosis  Rheumatoid Arthritis  Migraine  Diabetes  Other Indications  Key Geographies  North America  Europe  Asia-Pacific  Rest of the World The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. The opinions and insights presented in the report were influenced by discussions held with several players in this industry. The study includes detailed transcripts of discussions held with the following individuals:  David Daily (CEO and Co-founder, DALI Medical Devices)  Dennis Lee (Senior Program Officer in CMC, Bill & Melinda Gates Foundation)  Douglas Marenzi (Managing Director, PHC Injection Technologies)  Tsachi Shaked (Senior Marketing and BD Director, Injectable Drug Delivery Devices, Elcam Medical)  Jesse Fourt (Design Director, IDEO) To request a sample report - https://www.rootsanalysis.com/reports/293/request-sample.html Contact Information Roots Analysis Private Limited Gaurav Chaudhary +1 (415) 800 3415 ben.johnson@rootsanalysis.com Facebook - https://www.facebook.com/RootsAnalysis LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/ Twitter - https://twitter.com/RootsAnalysis